En forskningsundersøgelse, der undersøger, hvordan NNC0662-0419 virker sammen med p-piller og tømning af maven hos kvinder, der ikke kan blive gravide og har overvægt
En undersøgelse af effekten af NNC0662-0419 på farmakokinetikken af en oral kombinationsprævention (ethinylestradiol og levonorgestrel) og mavetømning hos kvinder uden barnepotentiale med overvægt eller fedme
The purpose of this clinical study is to find out if NNC0662-0419 is safe and effective to be taken together with other medicines, like birth control pills, and emptying of the stomach in women not able to become pregnant living with overweight or obesity. There are 3 study treatments in this study, participants will get all of the treatments, NNC0662-0419 the treatment being tested, Altavera a type of birth control pill, Acetaminophen a common type of mild painkiller.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Kansas
-
Overland Park, Kansas, Forenede Stater, 66212
- Altasciences Clinical Kansas, Inc.
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Female (sex assigned at birth) of non-childbearing potential.
- Age 18-64 years (both inclusive) at the time of signing the informed consent.
- Body weight more than or equal to (≥) 60.0 kilogram (kg).
- Considered to be generally healthy, except for overweight or obesity, based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Use of any medication containing glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), or amylin receptor agonism before screening.
- Any contraindications for the use of the oral contraception used in the study according to the Altavera Product Information.
- Use of hormone replacement therapy within 28 days before screening or intention to initiate treatment with hormone replacement therapy during the study.
- Use of prescription medicinal products or non-prescription drugs, including any herbal medicine known to interfere with the metabolic CYP pathways, such as perikon (St. John's Wort), within 14 days (or within 5 half-lives of the medicinal product, whichever is longest) of screening, with the exception of use of routine vitamins (vitamins used within a normal dose reference interval), occasional use of acetaminophen, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation.
- Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator.
- History of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: NNC0662-0419 with oral contraceptive (Altavera) and acetaminophen
Participants will receive once-weekly subcutaneous NNC0662-0419, with multiple doses administered over the treatment period. An oral contraceptive will be administered as a number of tablets per treatment period, with dosing conducted under supervised conditions. In addition, a single dose of acetaminophen will be administered as part of a standardized meal during treatment period. |
Once-weekly subcutaneous NNC0662-0419 will be administered using a pen injector An oral contraceptive Altavera [levonorgestrel (LN) 0.15 milligram (mg) and ethinyl estradiol (EE) 0.03 mg] will be administered orally. A single dose of acetaminophen will be administered orally. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Area under curve (AUC) 0-24 h, EE, steady state (SS): The area under the EE plasma concentration-time curve (pre-dose to 24 hours post-dose)
Tidsramme: Day 8 and 1 day after last NNC0662-0419 dose
|
Measured as picograms per milliliter (h*pg/mL) |
Day 8 and 1 day after last NNC0662-0419 dose
|
|
AUC0-24h, LN, SS: The area under the LN plasma concentration-time curve (pre-dose to 24 hours post-dose)
Tidsramme: Day 8 and 1 day after last NNC0662-0419 dose
|
Measured as h*pg/mL |
Day 8 and 1 day after last NNC0662-0419 dose
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum concentration (Cmax), EE, SS: Maximum observed EE plasma concentration (pre-dose to 24 hours post-dose)
Tidsramme: Day 8 and 1 day after last NNC0662-0419 dose
|
Measured as pg/mL |
Day 8 and 1 day after last NNC0662-0419 dose
|
|
Cmax, LN, SS: Maximum observed LN plasma concentration (pre-dose to 24 hours post-dose)
Tidsramme: Day 8 and 1 day after last NNC0662-0419 dose
|
Measured as pg/mL |
Day 8 and 1 day after last NNC0662-0419 dose
|
|
AUC0-60min, para: The area under the paracetamol plasma concentration-time curve (pre-dose to 60 minutes post-dose) following a standardised meal
Tidsramme: Day 1 and 1 day after 3rd NNC0662-0419 dose on highest dose step
|
Measured as microgram per milliliter (h*μg/mL) |
Day 1 and 1 day after 3rd NNC0662-0419 dose on highest dose step
|
|
AUC0-300min, para: The area under the paracetamol plasma concentration-time curve (pre-dose to 300 minutes post-dose) following a standardised meal
Tidsramme: Day 1 and 1 day after 3rd NNC0662-0419 dose on highest dose step
|
Measured as h*μg/mL |
Day 1 and 1 day after 3rd NNC0662-0419 dose on highest dose step
|
|
Cmax, para; Maximum observed paracetamol plasma concentration (pre-dose to 300 minutes post-dose) following a standardised meal
Tidsramme: Day 1 and 1 day after 3rd NNC0662-0419 dose on highest dose step
|
Measured as μg/mL |
Day 1 and 1 day after 3rd NNC0662-0419 dose on highest dose step
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Ernæringsforstyrrelser
- Overernæring
- Kropsvægt
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Tegn og symptomer
- Overvægtig
- Fedme
- Lægemidlers fysiologiske virkninger
- Reproduktionskontrolmidler
- Præventionsmidler, kvinder
- Præventionsmidler
- Organiske kemikalier
- Farmakologiske handlinger
- Kemiske handlinger og anvendelser
- Terapeutiske anvendelser
- Anilider
- Amider
- Anilinforbindelser
- Aminer
- Acetanilider
- Acetaminophen
- Præventionsmidler, Oral
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NN9662-8158
- U1111-1328-3457 (Anden identifikator: WHO)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .